Age-Related Macular Degeneration

Experts wrap up their discussion by highlighting key takeaways on the treatment of retinal diseases with anti-vascular endothelial growth factor (Anti-VEGF) therapies.

Experts discuss emerging gene therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) and key end points considerations.

Apellis Pharmaceuticals identified internal structural variations in the 19-gauge filter needle included in certain injection kits for pegcetacoplan injection, the first FDA-approved treatment for geographic atrophy.

With approval, aflibercept 8 mg becomes the first and only treatment approved in wet AMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.

Initial real-world experience with ranibizumab biosimilar agents revealed no unexpected adverse outcomes across 16 retina centers, with similar efficacy to reference ranibizumab.

Results from the CT-P42 3.1 Study indicate the therapeutic equivalence of the aflibercept biosimilar, CT-P42, to the reference product in eyes with DME.

In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 presentations from ASRS 2023. The discussion centered around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT.

Experts discuss prospective therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) treatment.

Experts discuss the recent PULSAR and PHOTON studies with high dose aflibercept (8mg) and how they educate patients about this treatment approach.

Real-world data show the benefits of DEX implants prior to cataract surgery to achieve sufficient postoperative inflammation management and limit deterioration.

Comparable efficacy, including of BCVA, CST, and fluid status between SB15 and reference aflibercept, was maintained up to Week 56 in nAMD eyes.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our July 2023 month-in-review features a recap of conference coverage from the ASRS 41st Annual Scientific Meeting.

A new analysis suggests pseudomyopia was an independent risk factor for myopia development among school-aged children in China.

Results from the real-world AUSSIEDEX study suggest dexamethasone implant significantly improved anatomic outcomes at 52 weeks and showed no new safety concerns.

Large learning model-based platforms provide largely inaccurate responses to questions concerning vitreoretinal disease and remain inconsistent on repeat queries.

New study data indicate the growing knowledge of artificial intelligence chatbots in ophthalmology. We are joined by 3 study investigators to discuss what this could mean for the field overall and its impact on patient care.

New 96-week data from PULSAR show patients treated with aflibercept 8 mg achieved good durability and maintained visual acuity gains from year 1 through year 2 of study.

Anatomic and visual improvements with high-dose aflibercept in CANDELA indicate a potential therapeutic benefit over aflibercept 2 mg, despite not achieving statistical significance.

Results from FARETINA-DME indicate a majority of eyes with DME began extending treatment intervals after 1-2 initial doses of faricimab.

Positive topline results from the phase 3 trial suggest once-daily OCS-01 met both primary trial endpoints for the treatment of inflammation and pain following cataract surgery.

Last week's FDA approval of avacincaptad pegol marked the second approved treatment for geographic atrophy in 2023. Here, 4 retina specialists discuss the complement inhibitor and what it could represent for patients with GA.

Data from PK profiles and safety analyses of intravitreal sozinibercept suggest the promise of the drug in combination with standard anti-VEGF agents for AMD and DME.

The approval is the second granted to a geographic atrophy drug that targets the complement pathway.

Presented at ASRS 2023, results from a posthoc analysis of YOSEMITE/RHINE suggest a potential anti-fibrotic effect of faricimab versus aflibercept in eyes with DME.

Presented at ASRS 2023, an analysis of the Portal trial suggests the efficacy and safety of PDS with ranibizumab was maintained over 5 years in patients with nAMD.